AREXVY Indication and Data Update

Posted Wednesday 30 April 2025 | GSK

Join us for an exclusive webinar event.

Dr Cedric 'Jamie' Rutland joins us virtually to introduce AREXVY's expanded indication. Don't miss this opportunity to learn about the latest in RSV vaccination for older adults and what it means for Australian patients. 

AREXVY is indicated for active immunisation for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in:

• adults aged 60 years and older; 
• adults aged 50-59 who are at increased risk for RSV disease. 

Learning Objectives:

• Understand the burden of RSV disease in older adults aged >50 years
• Explore the expanded indication of AREXVY for adults aged 50-59 at increased risk and what this means for Australian patients
• Understand the efficacy and safety data of AREXVY in adults aged >60 years
• Develop effective strategies to implement AREXVY in your clinical practice.